| Firm | Analyst |
|---|---|
| BAIRD | Christopher Chen, PhD |
| CANACCORD GENUITY | Sumant Kulkarni |
| CANTOR FITZGERALD | Pete Stavropoulos, PhD |
| CHARDAN | |
| EVERCORE ISI | Gavin Clark-Gartner |
| HC WAINWRIGHT | Patrick Trucchio |
| JONES TRADING | Justin Walsh |
| LEERINK | Marc Goodman |
| LIFESCI CAPITAL | Francois Brisebois |
| MAXIM GROUP | Michael Okunewitch |
| NEEDHAM | Ami Fadia |
| OPPENHEIMER & CO. INC. | Jay Olson |
| RBC CAPITAL MARKETS | Brian Abrahams, MD; Leonid Timashev, PhD |
| ROTH CAPITAL PARTNERS | Jason Wittes |
Definium Therapeutics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Definium Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Definium Therapeutics or its management. Definium Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.